COMPANY PROFILE

Chemclin Diagnostics / 科美诊断

Explore full profile

LiCA chemiluminescence IVD reagents and instruments (STAR 688468)

ChinaFounded 2007Biotech & Life Sciences

Valuation $250–500M Last recorded · 2026

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Chemclin Diagnostics / 科美诊断

Beijing STAR-listed clinical chemiluminescence IVD OEM (Chemclin Diagnostics / 科美诊断; STAR 688468) develops LiCA light-initiated chemiluminescence reagents and instruments plus enzymatic CC-series systems for clinical immunology labs. Founded in 2007 and headquartered in Beijing Haidian Yongfeng, Chemclin is an active listed mid-size China IVD manufacturer beyond YHLO/Hotgen and Maccura peers — not an acquired shell.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2007
Headquarters: China
Employees: 22
Open positions: None listed
Dealroom signal: 24.3/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Health Diagnostics, IVD, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
GROWTH EQUITY VCOther financing	Aug 2018	$293M	—	Legend Capital · Matrix Partners China · FTZ Fund Management · Highlight Capital	—
ACQUISITIONOther financing	Jan 2013	$0	—	Actis	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Chemclin Diagnostics / 科美诊断 website traffic

Latest recorded traffic for Chemclin Diagnostics / 科美诊断 is 290 monthly website visits, down 77.7% over the last three months. Chemclin Diagnostics / 科美诊断's team grew 0% over the past year.

Latest monthly visits290 3-month web change-77.7% 1-year team growth0%

Monthly website visitsJan 2017–Apr 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NGNucleus GenomicsOffers an all-in-one DNA health test, combining whole-genome sequencing with lifestyle factors to deliver the comprehensive insights into health and well-being	New York City, United States	Operational	44	$32M	$56M
PRPrecirixCamelid-derived radiopharmaceuticals for targeted cancer therapy	Jette, Belgium	Operational
L3LUMINELLE 360An innovative femtech solution offering convenient, cost-effective office Hysteroscopy and Cystoscopy procedures	Raleigh, United States	Acquired
MDMLA DiagnosticsDeveloped a revolutionary prognostic test for early stage melanoma	Maastricht, Netherlands	Operational
MEMettleAILeveraging ML/AI to predict substance abuse relapse before it happens	Toronto, Canada	Operational
CDCNA DiagnosticsA molecular diagnostics company developing novel diagnostic tests for a spectrum of complex diseases	Calgary, Canada	Operational
VIVitroScanDedicated to delivering predictive diagnostic testing to support better informed treatment decisions for cancer patients	Leiden, Netherlands	Operational
MBMantle BiotechMantle Biotech develops low-cost and accurate medical diagnostics to address unmet medical needs	Cambridge, United States	Operational

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

0 profiles shownExplore the complete relationship graph →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

WGWI Harper Group
N4N47
SCSB China Capital
SPSAIF Partners

Series B and later6 investors entered at this stage

LCLegend Capital
MCMatrix Partners China
FMFTZ Fund Management
HCHighlight Capital
CRChina Renaissance
PVPing An Ventures

Other known investors1 additional known investor

ACActis

Talent

Book a demo to see the people

Team profiled 2 named & role-tagged

Founders /100 quality score

Key operators 1 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country

Workforce by country

1 countries with
team presence

🇨🇳 China100%

1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Chemclin Diagnostics / 科美诊断 on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Chemclin Diagnostics / 科美诊断’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.